HAMBURG, GERMANY / ACCESSWIRE / July 21, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into a comprehensive partnership ...

VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that ...

At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock sat down with Dr Michael Bauer, CEO of Quantro Therapeutics, about his company’s novel approach to gene transcription factor control.

The issuer is solely responsible for the content of this announcement. QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform Austrian ...

VIENNA, Austria, June 04, 2024 (GLOBE NEWSWIRE) -- QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that ...

Deal represents part of Boehringer Ingelheim’s strategy to provide breakthrough cancer therapies Deal represents part of Boehringer Ingelheim’s strategy to provide breakthrough cancer therapies ...

Ryan is a tech/science writer, skeptic, lover of all things electronic, and Android fan. In his spare time he reads golden-age sci-fi and sleeps, but rarely at the same time. His wife tolerates him as ...

QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammation QUANTRO CEO Dr. Michael Bauer to ...

Quantro Therapeutics, a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company has reached a key milestone in its joint R&D programme ...